Michael Raab sold 41,666 shares of common stock for a total of approximately $243,000, with the transaction executed at around $5.84 per share on March 16, 2026. The transaction represented 2.21% of M
WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signific
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines t
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment Post
WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet signific
Michael Raab sold 41,666 shares directly on Feb. 24, 2026, for approximately $261,000 at a weighted-average price of $6.25 per share. The sale represented 2.19% of Raab's direct holdings at the time o
Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) CEO Michael Raab sold 45,982 shares of the firm's stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price o
Ardelyx, Inc. (NASDAQ: ARDX - Get Free Report) Director David Mott bought 333,333 shares of the business's stock in a transaction on Friday, February 20th. The shares were acquired at an average cost
Why Ardelyx's Offensive Strategy Doesn't Move The Needle
Ardelyx, Inc. delivered strong FY 2025 revenue growth, driven by Ibsrela, but missed on earnings due to sharply higher SG&A and R&D costs. Ibsrela's accelerating momentum underpins management's guidan
Ardelyx Inc. (NASDAQ: ARDX) shares are down during Friday's premarket session following a recent financial update for the fourth quarter of 2025.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Stre

Ardelyx (ARDX) Reports Break-Even Earnings for Q4

06:10pm, Thursday, 19'th Feb 2026
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.02 per share a year ago.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE